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69 Altered calpain caspase cascade in CF cells
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Cystic Fibrosis (CF) is a common, lethal, autosomal recessive disease caused by
mutations in the gene encoding the cystic ﬁbrosis transmembrane conductance
regulator (CFTR). In the most frequent mutation (F508del), F508del-CFTR protein
is misfolded and retained in the endoplasmic reticulum (ER). We previously showed
that the unfolded protein response (UPR) may be triggered in CF. Since prolonged
UPR activation leads to apoptosis via the calcium-calpain-caspase-12-caspase-3
cascade and because apoptosis is altered in CF, our aim was to compare the
ER stress-induced apoptosis pathway between wild type (Wt) and F508del-CFTR
expressing cells. Using cells endegenously expressing the mutated CFTR and their
corrected counterparts we show that the calpain-caspase cascade is altered in
F508del-CFTR expressing cells. We propose that this alteration is involved in the
altered apoptosis triggering observed in CF.
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Low bone mass is common in patients with cystic ﬁbrosis (CF). Whether CFTR
activity in osteoblasts is a determinant factor in bone metabolism is yet unknown.
We investigate the impact of CFTR inhibition on the osteoprotegerin (OPG)/
receptor activator of nuclear factor-kB ligand (RANKL) system and prostaglandin
(PG) E2 production (two dominant and ﬁnal mediators of osteoclastogenesis) by
human osteoblasts. We used a model of primary osteoblast culture established
from trabecular bone fragments obtained from 45−75-year-old donors (n = 5).
Osteoblast cultures were validated according to the speciﬁc markers of osteoblastic
phenotype. By RT-PCR, we conﬁrmed the expression of CFTR mRNA in human
osteoblasts. Immunoﬂuorescence of cultured osteoblasts revealed the location of
CFTR in the cytoplasm. We also investigate the effect of inhibition of CFTR
(CFTRinh-172 inhibitor, 10mM for 72 h) on the basal and stimulated (TNF-a,
20 ng/ml, 4 h) production of OPG, RANKL, PGE2 and IL-8 by osteoblasts. We
demonstrate that resting and TNF-a-stimulated osteoblasts treated with CFTRinh-
172 signiﬁcantly released less OPG that untreated control osteoblasts. Interestingly,
this was accompanied by enhanced (a 3-fold increase) PGE2 and IL-8 (30%
increase) production in CFTRinh-172-treated osteoblasts. Our ﬁndings show for
the ﬁrst time that CFTR in osteoblasts plays a key role in the regulation of OPG, a
protector of bone resorption and PGE2, an inducer of inﬂammatory bone loss. Our
data suggest that lack of CFTR activity in osteoblasts may result in increased bone
resorption and osteoporosis in CF patients.
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Introduction: Cystic ﬁbrosis (CF) is a complex disease with multiple clinical symp-
toms. The clinical picture of the disease can’t be only explained by the malfunction
of CFTR various enzymatic disturbances has been described in CF patients. Some
proteolytic and glycolytic enzymes are at least partly involved in pathogenesis of
chronic Pseudomonas aeruginosa (PA) infection in CF patients.
Aim of the study: In our study we assessed the activity of cathepsin C (CatC),
cathepsin A (CatA), neuraminidase (Neu), beta-galactosidase (Gal) in mixed saliva
of 66 CF patients (CF) and 66 healthy controls (HC).
Methods: We assessed total concentration of sialic acid in saliva, correlation
of studied parameters with chronic PAinfection, the age of acquiring of chronic
infection. The Receiver Operating Characteristic (ROC) curve analysis was also
performed for assessed sialometric parameters.
Results: The activity of CatC and Gal was signiﬁcantly higher in CF group, the
activity of CatA was signiﬁcatnly lower in CF group and activity of Neu was
comparable in CF group and HC. Total sialic acid was signiﬁcantly higher in CF.
There was no correlation between the activity of studied enzymes and chronic PA
infection, but in ROC analysis the activity of CatC and Gal differentiate CF from
HC.
Conclusions: The activity of components of macromolecular complex in mixed
saliva of CF patients is higher comparing to HC. Despite the poor correlation with
PA infection, the enzyme activity can be useful as additional diagnostic test in
CF patients.
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Bronchial inﬂammation is a characteristic hallmark of Cystic Fibrosis lung disease.
Glucocorticoids (GC) are powerful anti-inﬂammatory molecules with widespread
spectrum of action. They are commonly used to ﬁght lung inﬂammation despite side
effects and controversial efﬁciency among patients. To better understand possible
actions of these molecules, our study focuses on plasma corticosteroid-binding
globulin (CBG). CBG is a plasma transport glycoprotein produced by the liver
that binds GC with high afﬁnity; about 90 % of circulating GC are bound to CBG.
According to the free hormone hypothesis, CBG is thought to primarily regulate the
bioavailability and metabolic clearance of GC. CBG could also address GC directly
to sites of inﬂammation. To investigate how CBG is regulated in inﬂammation
and CF context, its expression was assayed by qPCR in the liver of CF patients
(n = 9) vs healthy donors (n = 6). Interestingly, transcript measurements showed a
14 times increase in CF patients (p< 0.001) compared to donors. We are currently
studying, in hepatic cell lines, the regulation of CBG by inﬂammatory and/or anti-
inﬂammatory molecules to better understand the consequences of such upregulation
on GC efﬁciency.
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